NateraNTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 4,434
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
23% more repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 190
10% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 101
0.32% more ownership
Funds ownership: 94.67% [Q4 2024] → 95.0% (+0.32%) [Q1 2025]
1% less funds holding
Funds holding: 588 [Q4 2024] → 585 (-3) [Q1 2025]
8% less capital invested
Capital invested by funds: $19.8B [Q4 2024] → $18.2B (-$1.64B) [Q1 2025]
12% less call options, than puts
Call options by funds: $146M | Put options by funds: $165M
17% less funds holding in top 10
Funds holding in top 10: 29 [Q4 2024] → 24 (-5) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Piper Sandler David Westenberg | 27%upside $210 | Overweight Maintained | 15 May 2025 |
UBS Elizabeth Garcia | 32%upside $218 | Buy Maintained | 9 May 2025 |
Barclays Luke Sergott | 15%upside $190 | Overweight Maintained | 9 May 2025 |
Financial journalist opinion
Based on 5 articles about NTRA published over the past 30 days
